225. 先天性腎性尿崩症
[臨床試験数:12,薬物数:45(DrugBank:17),標的遺伝子数:30,標的パスウェイ数:63

Searched query = "Congenital nephrogenic diabetes insipidus", "Hereditary nephrogenic diabetes insipidus", "Nephrogenic diabetes insipidus"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-jRCTs031180369
12/04/201818/03/2019Tolvaptan for nephrogenic diabetes insipidusExploratory study of tolvaptan use for nephrogenic diabetes insipidus caused by mutation in vasopressin type 2 receptor - Tolvaptan use for NDI by V2R mutation Nephrogenic diabetes insipidus
Nephrogenic diabetes insipidus, polyuria;D018500
Starting tolvaptan from 60 mg and dose up to 90mg and 120mg in every 1 or 2 days.Makita NorikoNULLRecruiting>= 20age oldNot applicableBoth3Japan
2JPRN-UMIN000021708
2016/04/1818/04/2016A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene.A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene. - A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene. Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor geneAdministration of Tolvaptan once per day (60mg/day, 90mg/day, 120mg/day), each dose for two days.Department of Nephrology and Endocrinology, The University of Tokyo HospitalNULLRecruiting20years-oldNot applicableMale and Female3Not selectedJapan